Dr Orna Tal

Agency:

DMTP

Job Title:

Acting Director

Organisation:

Division of Medical Technology Policy

Tel:

972 3 5303278

Fax:

972 3 6354136

Email:

orna.tal@moh.health.gov.il

Website:

http://www.health.gov.il/english/pages_e/default.asp?pageid=28&parentid=15&catid=13&maincat=2

Address:

Ministry of Health, 2 Ben Tabai St, Jerusalem 93591, Israel

Agency Member Since:

12/9/2002

Additional Contacts:

Miriam Ines Siebzehner (MiriS@gertner.health.gov.il), Nina Hakak (NinaH@gertner.health.gov.il)

EAAS Name:

DMTP

EAAS Host Organisation:

Ministry of Health, Israel

EAAS Status:

Permanent

EAAS Main Output Language:

Hebrew

EAAS Description:

Background: DMTP supplements important ministerial activities at the Division of Medical Technology Policy at the Ministry of Health. Each assessment is summarized for professional consideration within the Ministry of Health as part of the decision-making process. Aim: DMTP focuses on screening and assessing new and emerging medical technologies, especially for candidateship for inclusion in the National List of Health Services. In addition attention is given to new technologies for infrastructure and hospital use. Main Customers: policy makers within the Ministry of Health. Output: Each assessment is summarized for professional consideration within the Ministry of Health as part of the decision-making process.

Main source of funding:

National health system - Department of Health or health services, Other: Ministry of Health

Purpose of EAAS:

• To inform decisions on coverage or reimbursement of health services
• Other:
• To Inform decision makers on current primary and secondary research

Types of technologies covered by EAAS:

• Pharmaceuticals (including vaccines)
• Devices (including imaging equipment)
• Diagnostics (diagnostic and prognostic biomarkers)
• Interventional procedures (e.g. surgery)
• Programmes (e.g. screening and vaccination programmes)
• Health care settings (e.g. organisational changes, professional boundaries)
• Other:
• Rehabilitation and prevention

Main customers of EAAS:

• National Government Health Departments & Ministers
• Regional, State or Provincial Government
• Health services purchasers, commissioners or other decision makers
• Health care providers e.g. hospitals
• Health care professionals, medical advisors or clinical experts
• National research & development programme
• Insurance or re-imbursement organisations

Contents of Main Output from EAAS:

• Potential for significant health service impact
• Safety and efficacy
• Assessment of clinical effectiveness
• Other:
• Social and ethical standpoints including quality of life considerations